Due to their ability to improve clinical outcomes and treat a more comprehensive patient population, vascular endothelial growth factor (VEGF) inhibitors have become the standard treatment used in wet AMD. 

Dominant brands Eylea and Vabysmo have become the standard treatment due to their ability to improve clinical outcomes and treat a broader patient population. Despite the availability of cheaper off-label bevacizumab, branded biologic therapies continue to generate substantial revenues due to their high prices and recurring treatment schedules.

This Datamonitor Healthcare report contains a Disease Analysis module.